Safety and immunogenicity of the malaria candidate vaccines FP9CS and MVA CS in adult Gambian men

被引：21

作者：

Imoukhuede, E. B. ^{[1
]}

Berthoud, T.

Milligan, P.

Bojang, K.

Ismaili, J.

Keating, S.

Nwakanma, D.

Keita, S.

Njie, F.

Sowe, M.

Todryk, S.

Laidlaw, S. M.

Skinner, M. A.

Lang, T.

Gilbert, S.

Greenwood, B. M.

Hill, A. V. S.

机构：

[1] MRC Labs, Banjul, Gambia

[2] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England

[3] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England

[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England

来源：

VACCINE | 2006年 / 24卷 / 42-43期

基金：

英国惠康基金;

关键词：

malaria vaccines; prime-boost; immunogenicity;

D O I：

10.1016/j.vaccine.2006.06.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodiumfalciparunt circurnsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：6526 / 6533

页数：8

共 30 条

[1] Safety and immunogenicity of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP in semi-immune adult males [MIM-OK-87312]
Kai, O.
Mwacharo, J.
Bejon, P.
Lowe, B.
Molyneux, S.
Peshu, N.
Marsh, K.
Hill, A.
[J]. ACTA TROPICA, 2005, 95 : S421 - S421
[2] Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908]
Bejon, P.
Mwacharo, J.
Kai, O.
Lowe, B.
Todryk, S.
Peshu, N.
Gilbert, S.
Lang, T.
Marsh, K.
Hill, A.
[J]. ACTA TROPICA, 2005, 95 : S84 - S84
[3] A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
de Barra, Eoghan
Hodgson, Susanne H.
Ewer, Katie J.
Bliss, Carly M.
Hennigan, Kerrie
Collins, Ann
Berrie, Eleanor
Lawrie, Alison M.
Gilbert, Sarah C.
Nicosia, Alfredo
McConkey, Samuel J.
Hill, Adrian V. S.
[J]. PLOS ONE, 2014, 9 (12):
[4] PROTEOSOME-LIPOPEPTIDE VACCINES - ENHANCEMENT OF IMMUNOGENICITY FOR MALARIA CS PEPTIDES
LOWELL, GH
BALLOU, WR
SMITH, LF
WIRTZ, RA
ZOLLINGER, WD
HOCKMEYER, WT
[J]. SCIENCE, 1988, 240 (4853) : 800 - 802
[5] Safety and immunogenicity of prime-boost immunization of Kenyan adults with candidate malaria vaccines based on a chimpanzee Adenovirus and MVA
Ogwang, C.
[J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 : 43 - 43
[6] A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
Dunachie, SJ
Walther, M
Vuola, JM
Webster, DP
Keating, SM
Berthoud, T
Andrews, L
Bejon, P
Poulton, I
Butcher, G
Watkins, K
Sinden, RE
Leach, A
Moris, P
Tornieporth, N
Schneider, J
Dubovsky, F
Tierney, E
Williams, J
Heppner, DG
Gilbert, SC
Cohen, J
Hill, AVS
[J]. VACCINE, 2006, 24 (15) : 2850 - 2859
[7] Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
Ogwang, Caroline
Afolabi, Muhammed
Kimani, Domtila
Jagne, Ya Jankey
Sheehy, Susanne H.
Bliss, Carly M.
Duncan, Christopher J. A.
Collins, Katharine A.
Knight, Miguel A. Garcia
Kimani, Eva
Anagnostou, Nicholas A.
Berrie, Eleanor
Moyle, Sarah
Gilbert, Sarah C.
Spencer, Alexandra J.
Soipei, Peninah
Mueller, Jenny
Okebe, Joseph
Colloca, Stefano
Cortese, Riccardo
Viebig, Nicola K.
Roberts, Rachel
Gantlett, Katherine
Lawrie, Alison M.
Nicosia, Alfredo
Imoukhuede, Egeruan B.
Bejon, Philip
Urban, Britta C.
Flanagan, Katie L.
Ewer, Katie J.
Chilengi, Roma
Hill, Adrian V. S.
Bojang, Kalifa
[J]. PLOS ONE, 2013, 8 (03):
[8] Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
Mensah, Victorine A.
Roetynck, Sophie
Kanteh, Ebrima K.
Bowyer, Georgina
Ndaw, Amy
Oko, Francis
Bliss, Carly M.
Jagne, Ya Jankey
Cortese, Riccardo
Nicosia, Alfredo
Roberts, Rachel
D'Alessio, Flavia
Leroy, Odile
Faye, Babacar
Kampmann, Beate
Cisse, Badara
Bojang, Kalifa
Gerry, Stephen
Viebig, Nicola K.
Lawrie, Alison M.
Clarke, Ed
Imoukhuede, Egeruan B.
Ewer, Katie J.
Hill, Adrian V. S.
Afolabi, Muhammed O.
[J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
[9] Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults A phase I clinical trial
Rowland, Rosalind
Pathan, Ansar A.
Satti, Iman
Poulton, Ian D.
Matsumiya, Magali M. L.
Whittaker, Megan
Minassian, Angela M.
O'Hara, Geraldine A.
Hamill, Matthew
Scott, Janet T.
Harris, Stephanie A.
Poyntz, Hazel C.
Bateman, Cynthia
Meyer, Joel
Williams, Nicola
Gilbert, Sarah C.
Lawrie, Alison M.
Hill, Adrian V. S.
McShane, Helen
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (01) : 50 - 62
[10] A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
Bejon, Philip
Mwacharo, Jedidah
Kai, Oscar
Mwangi, Tabitha
Milligan, Paul
Todryk, Stephen
Keating, Sheila
Lang, Trudie
Lowe, Brett
Gikonyo, Caroline
Molyneux, Catherine
Fegan, Greg
Gilbert, Sarah C.
Peshu, Norbert
Marsh, Kevin
Hill, Adrian V. S.
[J]. PLOS CLINICAL TRIALS, 2006, 1 (06):

← 1 2 3 →